HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

3rd Edition of International Conference on Tissue Engineering and Regenerative Medicine

August 21-23, 2023

August 21 -23, 2023 | London, UK
TERMC 2020

Maria Jesus Rodrigo Sanjuan

Maria Jesus Rodrigo Sanjuan, Speaker at 
Regenerative Medicine Conference
Miguel Servet University Hospital, Spain
Title : Monitorization of the neuroprotective formulation Brimonidine-Laponite over 6 months in a glaucoma murine


Brimonidine (Bri) is an ocularhypopressure drug widely used for glaucoma treatment as eye drops, and recent studies also showed to be protective to neuroretinal tissue. Intraocular administration needs of long-lasting delivery systems in order to decrease sight-threatened side effects and increase patient’s compliance. In this study, the nano-clay Laponite® (Lap) was used as a biocompatible carrier with the aim of obtaining intraocular sustained levels of Brimonidine. Bilateral glaucoma by Morrison’s model was induced in 60 Long Evans rats and Bri-Lap formulation was injected into the vitreous humor in right eyes at baseline, and 31 animals served as controls. To study clinical safety, ocular signs and intraocular pressure (with Tonolab®; TiolatOy Helsinki, Finland) were monitored weekly. Functional and structural studies were performed at 0-8-12- 18-24 weeks to analyze the neuroretinal tissue, by in vivo electroretinography (ERG)(Roland consult® RETIanimal ERG, Germany), high-resolution optical coherence tomography (OCT) (High Resolution-OCT Spectralis, Heidelberg® Engineering, Germany) and histological studies, respectively. For drug monitorization Bri-Lap quantification by high performance liquid chromatography mass spectrometry (HPLC-Mss), pharmacokinetic study and vitreous signal intensity by in vivo OCT were analyzed. Bri-Lap formulation was well tolerated, early decreased the intraocular pressure (17.36 ±4.10vs 25.26±3.69mmHg; p<0.001), exerted both structural -increased thickness of whole retina and axons of retinal ganglion cell (RGC) (25.60±1.67 vs 21.57±5.59; p=0.038) by OCT and cell count (23.00±0.39 vs 20.66±0.98; p=0.040) compared to non-treated eye- and functional -by maintaining higher amplitude ERG of RGC (41.20±8.75 vs 14.60±12.60; p=0.015)- neuroprotective effect up to 6 months. Ocular levels of Bri-Lap progressively decreased (intensity = 30 to 0.22) over follow-up being detectable up to 6 months. In conclusion, Laponite allowed intraocular sustained delivery of Brimonidine. A single eye injection of Bri-Lap formulation exerted both functional and structural protection of the neurorretinal tissue over 6 months